1. RYANODEX [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2014.
  2. Data on file. Eagle Pharmaceuticals, Inc.
  3. Managing an MH crisis. Malignant Hyperthermia Association of the United States website. http://www.mhaus.org/healthcareprofessionals/managing-a-crisis. Accessed June 30, 2014.
  4. Rosenberg H, Sambuughin N, Riazi S, Dirksen R. Malignant hyperthermia susceptibility. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle.
  5. FAQs: General MH questions. Malignant Hyperthermia Association of the United States website. http://www.mhaus.org/faqs/about-mh. Accessed June 30, 2014.
  6. Rosenberg H. Current state of malignant hyperthermia and the use of dantrium iv as treatment. Anesthesiology News. 2010:20-21.
  7. Brandom BW. Cases from the North American MH Registry/MHAUS [1992 through 2012].
  8. Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 2014;118(2):381-387.
  9. Dantrium Intravenous [package insert]. Rochester, MI: JHP Pharmaceuticals, LLC; 2008.
  10. Revonto [package insert]. Louisville, KY: US WorldMeds, LLC; 2011.
  11. Schütte JK, Becker S, Burmester S, Starosse, et al. Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and susceptible pigs. Euro J of Anesth. 2011: 28(4)256-264.
  12. FAQs: Stocking an MH cart. Malignant Hyperthermia Association of the United States website. http://www.mhaus.org/faqs/stocking-an-mh-cart. Accessed June 30, 2014.
  13. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg. 2010;110(2):498-507.